Actelion - Facts and Figures

A Global Biopharmaceutical Leader


Actelion	Actelion Ltd Actelion Pharmaceuticals Ltd
Corporate structure	Public company, listed at the Swiss stock exchange
Founded	December 17, 1997
Founding team	Jean-Paul Clozel, Walter Fischli, Thomas Widmann, Martine Clozel, Andre Mueller
Head office	Actelion Ltd & Actelion Pharmaceuticals Ltd Gewerbestrasse 16 4123 Allschwil, Switzerland tel. + 41 61 565 65 65 fax + 41 61 565 65 00
Global presence	Actelion has subsidiaries with marketing and sales in 23 countries, covering all key pharmaceutical markets worldwide: Actelion Subsidiaries
Products	Tracleer (bosentan), a dual endothelin receptor antagonist, is approved as oral treatment for WHO Class III or IV pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder which severely compromises the function of the lungs and heart. See Regulatory Status Zavesca (miglustat) is a small molecule oral therapy for the treatment of type 1 Gaucher disease, a genetic lipid storage disorder. Ventavis (iloprost) is an inhaled formulation of iloprost, approved for the treatment of pulmonary arterial hypertension. Ventavis®, the only inhaled PAH therapy on the US market.